Research programme: Core-2 GlcNAc-T inhibitors - Inflazyme
Alternative Names: Core-2 GlcNAc-T inhibitors research programme - Inflazyme; Core-2 transferase inhibitors research programme - Inflazyme; IPL27 series research programme - Inflazyme; Research programme: Core-2 transferase inhibitors - Inflazyme; Research programme: IPL27 series - InflazymeLatest Information Update: 16 Jul 2016
At a glance
- Originator Inflazyme Pharmaceuticals
- Class Small molecules
- Mechanism of Action Core 2 GlcNAc transferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Diabetes mellitus; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Canada (PO)
- 17 Jun 2003 GLYCODesign has been acquired by Inflazyme Pharmaceuticals
- 05 Feb 2003 GLYCODesign has regained all rights to Core-2 inhibitors